Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Nab-paclitaxel and carboplatin showed better treatment response compared with cremophor-based
paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer,
especially for squamous cell cancer. The regimen of weekly nab-paclitaxel, carboplatin and
concurrent radiotherapy was well tolerated in a phase I study. Given nab-paclitaxel,
carboplatin and concurrent radiotherapy in patients with local advanced squamous cell lung
cancer may have promising result.